ATF2 and prostate carcinoma: Percentages of patients showing positive immunohistochemical reactions to p-ELK-1, ATF-2 [31], p50 and p65 [5] in normal prostate (NP), benign prostatic hyperplasia (BPH) and prostatic carcinoma (PC) and average optical densities of immunostaining in positive patients.